<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911313</url>
  </required_header>
  <id_info>
    <org_study_id>MU- 059</org_study_id>
    <secondary_id>FMH-012-G</secondary_id>
    <nct_id>NCT00911313</nct_id>
  </id_info>
  <brief_title>Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome</brief_title>
  <official_title>Letrozole Versus Combined Metformin and Clomiphene Citrate for Ovulation Induction in Clomiphene-Resistant Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and determine the efficacy of letrozole
      administration to that of combined metformin and Clomiphene in infertile women with
      polycystic ovary syndrome (PCOS) not responding to treatment with Clomiphene alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Withdrawal bleeding was achieved using 10 mg of dydrogesterone tablets for 10 days before
      stimulation. In the letrozole group, 2.5 mg of letrozole oral tablets (Femara; Novartis
      Pharma Services, Switzerland) daily from day 3 of the menses for 5 days, whereas all patients
      in the combined metformin-CC group) received metformin HCl [Cidophage速; Chemical Industries
      Development(CID), Cairo, Egypt], 500 mg three times daily for 6-8 weeks. Then after the end
      of this period, they received 150 mg CC (Clomid速; Global Napi Pharmaceuticals, Cairo, Egypt)
      for 5 days starting from day 3 of menstruation. Patients continued treatment for three
      successive cycles using the same protocol. Metformin was stopped only when pregnancy was
      documented.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Principally the ovulation rate as well as the number of growing and mature follicles, serum E2 (pg/ml), serum P (ng/mL), and endometrial thickness (mm).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of pregnancy and miscarriage.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin-CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole tablets (Femara; Novartis Pharma, Switzerland)</intervention_name>
    <description>2.5 mg letrozole daily from day 3 of the menses for 5 days</description>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin HCl (Cidophage速; CID,Cairo, Egypt)</intervention_name>
    <description>metformin HCl 1500 daily for 6-8 weeks</description>
    <arm_group_label>Metformin-CC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC (Clomid速; Global Napi Pharmaceuticals, Cairo, Egypt)</intervention_name>
    <description>150 mg CC for 5 days starting from day 3 of menstruation</description>
    <arm_group_label>Metformin-CC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CC resistant PCOS

        Exclusion Criteria:

          -  Congenital adrenal hyperplasia

          -  Cushing syndrome

          -  Androgen secreting tumors
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem Abu Hashim, MD. MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarek Shokair, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Badawy, MD.PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospitals,OB/GYN department</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006 Feb;85(2):277-84. Review.</citation>
    <PMID>16595197</PMID>
  </reference>
  <reference>
    <citation>Siebert TI, Kruger TF, Steyn DW, Nosarka S. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril. 2006 Nov;86(5):1432-7. Epub 2006 Sep 27. Review.</citation>
    <PMID>17007847</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2009</study_first_posted>
  <last_update_submitted>May 28, 2009</last_update_submitted>
  <last_update_submitted_qc>May 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hatem Abu Hashim, Associate Prof. of OB/GYN</name_title>
    <organization>Mansoura Faculty of Medicine, Mansoura University.</organization>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>clomiphene resistance</keyword>
  <keyword>letrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

